T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
Recruiting
Evaluating Iron-Dependent Biomarkers of Malignant Glioma (WHO Grade IV) Progression
Who can join
Ages 21 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age \> 21 years * New pathologically confirmed diagnosis of WHO grade IV malignant glioma * KPS \> 60 * Ability to give informed consent for standard of care chemotherapy and radiation therapy on the MR Linac and to study procedures for the protocol Exclusion Criteria: * History of previous malignancy other than non-melanoma skin cancer in the previous 5 years * History of iron metabolic disorder such as hemochromatosis * Inability to undergo MR studies due to size, claustrophobia, or metal implants or devices
About the study
This clinical trial studies whether T2 star (T2\*) magnetic resonance imaging (MRI) and biomarker blood testing can help predict how World Health Organization (WHO) grade IV gliomas (malignant gliomas) might change or progress over time.
What is being tested
- T2 (Observed)-Weighted Imaging (procedure)
- Biospecimen Collection (procedure)
- Magnetic Resonance Imaging (procedure)
Sponsor: John M. Buatti · Participants: 15 · Started: Oct 3, 2025
Contact the study team
- John Buatti, MD · Phone: (319) 356-7590
Official record on ClinicalTrials.gov — NCT07447531
Locations in the U.S.
| Iowa | University of Iowa Health Care, Iowa City |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.